The Kaplan–Meier survival analysis showed that IGF2BP3 mRNA expression was significantly associated with clinical endpoints such as distant metastasis-free survival (DMFS) and melanoma-specific survival (MSS). Here, IGF2BP3 is linked to melanoma.